Trial Profile
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Status:
Suspended
Phase of Trial:
Phase II/III
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 06 Dec 2023 Planned End Date changed from 31 Dec 2023 to 31 Jan 2026.
- 06 Dec 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Jan 2026.
- 23 Feb 2023 Planned number of patients changed from 514 to 278.